Gastric protection by nocloprost against aspirin damage in humans. Possible role of epidermal growth factor.
Ten healthy young male subjects took part in a double-blind, placebo-controlled crossover study to assess the effects of nocloprost on gastric microbleeding and endoscopic mucosal injury induced by the administration of aspirin (2.5 g). In addition, basal and pentagastrin-induced gastric acid and pepsin secretion and salivary and plasma contents of epidermal growth factor (EGF) were measured after placebo plus aspirin or nocloprost plus aspirin treatment in these subjects. Nocloprost (100 micrograms/dose) significantly reduced spontaneous gastric microbleeding and almost completely prevented gastric mucosal injury induced by aspirin. Nocloprost failed to affect basal and pentagastrin-stimulated gastric acid and pepsin secretion but increased significantly the salivary outputs and plasma concentrations of EGF. In conclusion, nocloprost is effective in preventing gastric injury by aspirin even at a non-antisecretory dose, and this protection may involve an excessive release of EGF.
Konturek
S J
SJ
Institute of Physiology, Academy of Medicine, Cracow, Poland.
Konturek
J W
JW
Kwiecien
N
N
Obtułowicz
W
W
Oleksy
J
J
Hebzda
Z
Z
Amon
I
I
D000328:Adult; D001241:Aspirin / Q000009:adverse effects*; D004311:Double-Blind Method; D004815:Epidermal Growth Factor / Q000097:blood / Q000378:metabolism; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D005773:Gastroscopy; D006801:Humans; D008297:Male; D010434:Pepsin A / Q000378:metabolism; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D012463:Saliva / Q000378:metabolism; D014665:Vasodilator Agents / Q000627:therapeutic use*
D011461:Prostaglandins F, Synthetic; D014665:Vasodilator Agents; D004815:Epidermal Growth Factor; C048895:nocloprost; D010434:Pepsin A; D001241:Aspirin